Imagination over iteration

Coming together with backgrounds in biochemistry, chemistry, hardware, molecular biology, photonics, semiconductor chips, and software, our leadership has one thing in common: solving problems no one has thought of yet and disrupting industries to make a global impact on human health.

Leadership

Jonathan M. Rothberg, Ph.D.

Jonathan M.
Rothberg, Ph.D.

CEO, Founder, & Executive Chairman

[et_pb_section fb_built="1" admin_label="Member Bio" module_class="module-section member-bio" _builder_version="4.9.2" custom_padding="72px||208px||false|false"][et_pb_row column_structure="1_3,2_3" _builder_version="4.9.2" _module_preset="default" custom_padding="0px||0px||false|false"][et_pb_column type="1_3" _builder_version="4.9.2" _module_preset="default"][et_pb_image src="https://www.quantum-si.com/wp-content/uploads/2022/02/jonathan-dark.jpg" alt="Jonathan M. Rothberg, Ph.D." title_text="Jonathan M. Rothberg, Ph.D." _builder_version="4.9.2" _module_preset="default"][/et_pb_image][/et_pb_column][et_pb_column type="2_3" _builder_version="4.9.2" _module_preset="default"][et_pb_text module_class="module-text" _builder_version="4.9.2" _module_preset="default" hover_enabled="0" sticky_enabled="0"]

Jonathan M.
Rothberg, Ph.D.

CEO, Founder, & Executive Chairman

Jonathan M. Rothberg, Ph.D., is the founder of Quantum-Si and has served as the Executive Chairman of Quantum-Si’s board of directors since December 2015. He previously served as Quantum-Si’s CEO from December 2015 to November 2020. Dr. Rothberg is a scientist and entrepreneur who was awarded the National Medal of Technology and Innovation, the nation’s highest honor for technological achievement, by President Barack Obama for inventing and commercializing high-speed DNA sequencing. Dr. Rothberg is the founder of the 4Catalyzer medical technology incubator and the founder and Chairman of its companies: Quantum-Si, Butterfly Network, Inc., AI Therapeutics, Inc., Hyperfine Research, Inc., Tesseract Health, Inc., Liminal Sciences, Inc., and Detect, Inc. and Protein Engineering, Inc. These companies focus on using inflection points in medicine, such as deep learning, next-generation sequencing, and the silicon supply chain, to address global healthcare challenges. Dr. Rothberg previously founded and served as Chairman, Chief Executive Officer, and Chief Technology Officer of Ion Torrent Systems, Inc. from 2007 to 2010, and founded and served as Chairman and Chief Executive Officer of RainDance Technologies, Inc. from 2004 to 2009. From 1999 to 2007, Dr. Rothberg co-founded and served as Chairman of ClariFI, Inc., and from 1999 to 2006, he founded and served as Chairman, Chief Executive Officer and Chief Technology Officer of 454 Life Sciences Corporation. With 454 Life Sciences, Dr. Rothberg brought to market the first new way to sequence genomes since Sanger and Gilbert won the Nobel Prize for their method in 1980. With 454’s technology, Dr. Rothberg sequenced the first individual human genome, and with Svante Paabo he initiated the first large-scale effort to sequence ancient DNA (The Neanderthal Genome Project). Prior to 454 Life Sciences, Dr. Rothberg founded and served as Chairman and Chief Executive Officer of CuraGen Corporation from 1993 to 2004. His contributions to the field of genome sequencing include the first non-bacterial cloning method (cloning by limited dilution) and the first massively parallel DNA sequencing method (parallel sequencing by synthesis on a single substrate), concepts that have formed the basis for all subsequent next-generation sequencing technologies. Dr. Rothberg is an Ernst and Young Entrepreneur of the Year, is the recipient of The Wall Street Journal’s First Gold Medal for Innovation, SXSW Best in Show, Nature Methods First Method of the Year Award, the Connecticut Medal of Technology, the DGKL Biochemical Analysis Prize, and an Honorary Doctorate of Science from Mount Sinai. Dr. Rothberg is a member of the National Academy of Engineering, the Connecticut Academy of Science and Engineering, served as a trustee of Carnegie Mellon University and is an Adjunct Professor of Genetics at Yale University. Dr. Rothberg received his Ph.D., M.Phil. and M.S. in biology from Yale University and his B.S. in chemical engineering from Carnegie Mellon University.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Patrick Schneider,Ph.D

Patrick
Schneider, Ph.D.

President and Chief Operating Officer

[et_pb_section fb_built="1" admin_label="Member Bio" module_class="module-section member-bio" _builder_version="4.9.2" custom_padding="72px||208px||false|false" locked="off"][et_pb_row column_structure="1_3,2_3" _builder_version="4.9.2" _module_preset="default" custom_padding="0px||0px||false|false"][et_pb_column type="1_3" _builder_version="4.9.2" _module_preset="default"][et_pb_image src="https://www.quantum-si.com/wp-content/uploads/2022/05/Patrick-Schneider-Headshot@2x-1.jpg" alt="Patrick Schneider, Ph.D." title_text="Patrick Schneider Headshot@2x" _builder_version="4.9.2" _module_preset="default"][/et_pb_image][/et_pb_column][et_pb_column type="2_3" _builder_version="4.9.2" _module_preset="default"][et_pb_text module_class="module-text" _builder_version="4.9.2" _module_preset="default"]

Patrick Schneider, Ph.D.

President and Chief Operating Officer

Dr. Schneider has served in a number of roles at MilliporeSigma, including its predecessor entities (the life science business of Merck KGaA, Darmstadt, Germany), most recently as Senior Vice President, Strategy, Business Development and Innovation, and Chair of the Life Science Innovation Board from 2016 until April 2022, where he led strategy development, business development, and licensing for a global team of biologists, chemists and engineers. Prior to that, between 2006 to 2015, Dr. Schneider served as Vice President of the Bioscience Business Unit, Vice President of Research Content and Reagents Business, General Manager of New Business Initiatives R&D and Business Development, and Vice President of Research Reagents Business Unit. From 2003 to 2006, Dr. Schneider served as Vice President of Research & Development, Business Development & Scientific Affairs at Serologicals, Inc. Dr. Schneider received his Ph.D. in biology from University of California, Irvine.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Michael P. McKenna

Michael P.
McKenna

Executive Vice President, Product Development and Operations

[et_pb_section fb_built="1" admin_label="Member Bio" module_class="module-section member-bio" _builder_version="4.9.2" custom_padding="72px||208px||false|false"][et_pb_row column_structure="1_3,2_3" _builder_version="4.9.2" _module_preset="default" custom_padding="0px||0px||false|false"][et_pb_column type="1_3" _builder_version="4.9.2" _module_preset="default"][et_pb_image src="https://www.quantum-si.com/wp-content/uploads/2021/04/michael-mckenna-headshot.jpg" title_text="michael-mckenna-headshot" _builder_version="4.9.2" _module_preset="default" hover_enabled="0" alt="Michael P. McKenna" sticky_enabled="0"][/et_pb_image][/et_pb_column][et_pb_column type="2_3" _builder_version="4.9.2" _module_preset="default"][et_pb_text module_class="module-text" _builder_version="4.9.2" _module_preset="default"]

Michael P.
McKenna, Ph.D.

Executive Vice President, Product Development and Operations

Michael P. McKenna, Ph.D. has served as Quantum-Si’s Executive Vice President, Product Development and Operations since May 2022, and as Quantum-Si’s President and Chief Operating Officer since December 2014 to May 2022.Prior to joining Quantum-Si, Dr. McKenna served as Vice President, R&D at Life Technologies Corporation, a global biotechnology company, from August 2011 to July 2014, and as a consultant to Life Technologies from February 2011 to August 2011. Prior to that, Dr. McKenna served as Chief Scientific Officer of Tethys Bioscience, Inc., a diagnostics company, from August 2004 to February 2011, and as Vice President of Curagen Corporation, a biopharmaceutical company, from 1993 to 2003. Dr. McKenna received his B.S. in molecular biology and German from Carnegie Mellon University and his Ph.D. in biology from Yale University.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Todd Rearick

Todd
Rearick

Chief Technology Officer

[et_pb_section fb_built="1" admin_label="Member Bio" module_class="module-section member-bio" _builder_version="4.9.2" custom_padding="72px||208px||false|false"][et_pb_row column_structure="1_3,2_3" _builder_version="4.9.2" _module_preset="default" custom_padding="0px||0px||false|false"][et_pb_column type="1_3" _builder_version="4.9.2" _module_preset="default"][et_pb_image src="https://www.quantum-si.com/wp-content/uploads/2021/05/todd-rearick-headshot.jpg" title_text="todd-rearick-headshot" _builder_version="4.9.2" _module_preset="default" hover_enabled="0" alt="Todd Rearick" sticky_enabled="0"][/et_pb_image][/et_pb_column][et_pb_column type="2_3" _builder_version="4.9.2" _module_preset="default"][et_pb_text module_class="module-text" _builder_version="4.9.2" _module_preset="default"]

Todd Rearick

Chief Technology Officer

Todd Rearick has served as Quantum-Si's Chief Technology Officer since January 2019. Prior to that Mr. Rearick served as Chief Technology Officer at Hyperfine Research from January 2018 to January 2019, and as Systems Engineer from June 2014 to January 2018. Prior to that Mr. Rearick was an Engineering Fellow at Life Technologies from October 2010 to June 2014, and Principal Engineer for Ion Torrent from May 2008 to October 2010. Prior to that Mr. Rearick was a Software Manager at Raindance Technologies from June 2006 to May 2008, and held several positions at Sycamore Networks, a telecommunications equipment manufacturer, from April 1999 to June 2006. Mr. Rearick started his career with the Naval Undersea Warfare Center (NUWC) in New London, Connecticut from 1995 to 1998. Mr. Rearick earned his B.S. in Engineering Science from Penn State University.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Claudia Napal Drayton

Claudia Napal
Drayton

Chief Financial Officer

[et_pb_section fb_built="1" admin_label="Member Bio" module_class="module-section member-bio" _builder_version="4.9.2" custom_padding="72px||208px||false|false"][et_pb_row column_structure="1_3,2_3" _builder_version="4.9.2" _module_preset="default" custom_padding="0px||0px||false|false"][et_pb_column type="1_3" _builder_version="4.9.2" _module_preset="default"][et_pb_image src="https://www.quantum-si.com/wp-content/uploads/2021/04/Claudiea_Headshot-for-website@2x.jpg" title_text="Claudiea_Headshot for website@2x" _builder_version="4.9.2" _module_preset="default" hover_enabled="0" alt="Claudia Napal Drayton" sticky_enabled="0"][/et_pb_image][/et_pb_column][et_pb_column type="2_3" _builder_version="4.9.2" _module_preset="default"][et_pb_text disabled_on="on|on|on" admin_label="Text - with old bio for back up" module_class="module-text" _builder_version="4.9.2" _module_preset="default" disabled="on"]

Claudia Napal
Drayton

Chief Financial Officer

Claudia Drayton has served as Quantum-Si’s Chief Financial Officer since April 2021. She previously served as Chief Financial Officer of CHF Solutions, Inc., or CHFS, from January 2015 to April 2021. During her tenure as CFO of CHFS, Ms. Drayton guided the company through the acquisition of its commercial product line, and the completion of several public equity offerings to finance the company’s commercial expansion. Prior to joining CHFS, Ms. Drayton spent 15 years at Medtronic plc, or Medtronic, a $30 billion global leader in the medical device industry. During her tenure at Medtronic, Ms. Drayton held multiple senior managerial finance positions, culminating with an assignment in Europe serving as Chief Financial Officer of the peripheral vascular business from 2010 to 2012 and, more recently, as Chief Financial Person of the integrated health solutions business from 2012 to 2014. In these capacities, her responsibilities and experiences included profitability management, strategic planning, mergers and acquisitions, planning and forecasting, and implementation of financial best practices. Before joining Medtronic, Ms. Drayton was an audit and business advisory manager at Arthur Andersen LLP for seven years. Ms. Drayton received her M.B.A. from the University of Minnesota’s Carlson School of Management and her B.S. from the University of Mary Hardin-Baylor and is a Certified Public Accountant (inactive)

[/et_pb_text][et_pb_text module_class="module-text" _builder_version="4.9.2" _module_preset="default"]

Claudia Napal Drayton

Chief Financial Officer

Claudia Napal Drayton has served as Quantum-Si’s Chief Financial Officer since April 2021. She previously served as Chief Financial Officer of CHF Solutions, Inc., or CHFS, from January 2015 to April 2021. During her tenure as CFO of CHFS, Ms. Drayton guided the company through the acquisition of its commercial product line, and the completion of several public equity offerings to finance the company’s commercial expansion. Prior to joining CHFS, Ms. Drayton spent 15 years at Medtronic plc, or Medtronic, a $30 billion global leader in the medical device industry. During her tenure at Medtronic, Ms. Drayton held multiple senior managerial finance positions, culminating with an assignment in Europe serving as Chief Financial Officer of the peripheral vascular business from 2010 to 2012 and, more recently, as Chief Financial Person of the integrated health solutions business from 2012 to 2014. In these capacities, her responsibilities and experiences included profitability management, strategic planning, mergers and acquisitions, planning and forecasting, and implementation of financial best practices. Before joining Medtronic, Ms. Drayton was an audit and business advisory manager at Arthur Andersen LLP for seven years. Ms. Drayton received her M.B.A. from the University of Minnesota’s Carlson School of Management and her B.S. from the University of Mary Hardin-Baylor and is a Certified Public Accountant (inactive)

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]
Christian LaPointe

Christian
LaPointe

General Counsel

[et_pb_section fb_built="1" admin_label="Member Bio" module_class="module-section member-bio" _builder_version="4.9.2" custom_padding="72px||208px||false|false"][et_pb_row column_structure="1_3,2_3" _builder_version="4.9.2" _module_preset="default" custom_padding="0px||0px||false|false"][et_pb_column type="1_3" _builder_version="4.9.2" _module_preset="default"][et_pb_image src="https://www.quantum-si.com/wp-content/uploads/2021/04/christian-lapointe-headshot.jpg" title_text="christian-lapointe-headshot" _builder_version="4.9.2" _module_preset="default" hover_enabled="0" alt="Christian LaPointe" sticky_enabled="0"][/et_pb_image][/et_pb_column][et_pb_column type="2_3" _builder_version="4.9.2" _module_preset="default"][et_pb_text module_class="module-text" _builder_version="4.9.2" _module_preset="default"]

Christian
LaPointe, Ph.D.

General Counsel

Christian LaPointe, Ph.D. has served as Quantum-Si’s General Counsel since November 2020. Prior to joining Quantum-Si, Dr. LaPointe served as General Counsel at ArcherDX, Inc., a genomics company, from January 2015 to August 2019, and as Deputy General Counsel at ArcherDX from August 2019 to October 2020. Dr. LaPointe also served as General Counsel to Celsee, Inc., a single cell analysis solutions provider, from August 2019 to June 2020. Previously, Dr. LaPointe was General Counsel at Thrive Bioscience, Inc., a cell culture instruments and software company, from August 2014 to July 2019, General Counsel of the Enzymatics enzyme solutions unit of QIAGEN N.V., from March 2013 to January 2015, General Counsel of Axios Biosciences, LLC, an oncology drug discovery company, from December 2012 to December 2014, and a litigation attorney at the law firm Sherin and Lodgen LLP from April 2012 to March 2013. Dr. LaPointe received his B.S. in biochemistry from the University of New Hampshire, his Ph.D. in biochemistry from Dartmouth College and his J.D. from Suffolk University Law School.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

Results over rules:
Jonathan Rothberg

A prolific inventor and recipient of the Medal of Technology & Innovation under President Obama, Jonathan Rothberg pioneered high speed next-generation sequencing as well as semiconductor based sequencing. His next vision: Quantum-Si’s next-generation protein sequencing technology for truly accessible proteomics.

As the founder of several groundbreaking companies, Jonathan Rothberg has not only invented new industries, he has disrupted them as well.

Jonathan thrives on harnessing the power of semiconductor technology to create products for improving human health:

Ion Torrent

Ion Torrent disrupted the genomic sequencing industry—where slow and cost prohibitive technology was the norm—to make genomic sequencing more accessible to more brilliant minds.

Butterfly

Butterfly disrupted the ultrasound industry—where products are usually large, bulky, and hard to move around—bringing the portable ultrasound to the market and revolutionizing care in remote areas and regions.

Hyperfine

Hyperfine disrupted conventional MRIs—traditionally driving expensive and time consuming procedures—to put MRI imaging within reach of every patient regardless of location, in any healthcare facility in any country across the globe.

Other Jonathan Rothberg distinctions:

  • White House National Medal of Technology and Innovation, awarded by President Obama
  • Founder of Rothberg Institute for Childhood Diseases
  • The first individual named a World Economic Forum’s Technology Pioneer four separate times
  • Ernst and Young Entrepreneur of the Year
  • The Wall Street Journal’s First Gold Medal for Innovation Recipient